. . . . . . . "[Women with HER2-postive, hormone receptor-positive breast cancer and one or more mutations in PIK3CA were less likely to benefit from neoadjuvant chemotherapy and HER2-targeted therapies than those without a mutation, according to study results presented on December 12 at the 2013 San Antonio Breast Cancer Symposium in Texas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:12:24+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .